Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach

[1]  M. Cortina-Borja,et al.  Gender and race do not alter early-life determinants of clinical disease progression in HIV-1 vertically infected children , 2004, AIDS.

[2]  D. Harris,et al.  Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings , 2003, The Lancet.

[3]  O. Kirk,et al.  Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine , 2003, AIDS.

[4]  P. Keiser,et al.  Comparison of Efficacy of Efavirenz and Nevirapine: Lessons Learned for Cohort Analysis in Light of the 2NN Study , 2003, HIV Clinical Trials.

[5]  D. Mayers,et al.  A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients* , 2003, Journal of acquired immune deficiency syndromes.

[6]  K. Dalhoff,et al.  Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Magoni,et al.  Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission , 2003, AIDS (London).

[8]  G. Moyle.  NNRTI choice: has 2NN changed our practice? , 2003, The AIDS reader.

[9]  A. Osterhaus,et al.  Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV‐2‐infected patients , 2003, AIDS.

[10]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  W. Heneine,et al.  Antiretroviral therapy in HIV‐2‐infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire , 2003, AIDS.

[12]  E. Delaporte,et al.  Access to antiretroviral drugs and AIDS management in Senegal , 2003, AIDS.

[13]  D. Haas,et al.  Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial , 2003, AIDS.

[14]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[15]  E. Ribera,et al.  Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. , 2003, AIDS.

[16]  R. Wood,et al.  Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings , 2003, AIDS.

[17]  V. Soriano,et al.  Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.

[18]  K. Squires,et al.  Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects , 2003, Journal of acquired immune deficiency syndromes.

[19]  J. Rossert,et al.  Fanconi syndrome and renal failure induced by tenofovir: a first case report. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  T. Flanigan,et al.  Total Lymphocyte Count (TLC) Is a Useful Tool for the Timing of Opportunistic Infection Prophylaxis in India and Other Resource‐Constrained Countries , 2002, Journal of acquired immune deficiency syndromes.

[21]  Peter J Piliero,et al.  Atazanavir: a novel HIV-1 protease inhibitor , 2002, Expert opinion on investigational drugs.

[22]  R. Gelber,et al.  Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. , 2002, The Journal of infectious diseases.

[23]  O. Ramilo,et al.  Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. , 2002, The Journal of pediatrics.

[24]  D. Richman,et al.  A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). , 2002, AIDS research and human retroviruses.

[25]  G. Beall,et al.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.

[26]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[27]  L. Harrison,et al.  Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  N. Ives,et al.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy , 2002, AIDS (London).

[29]  A. Telenti,et al.  Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  M. Hughes,et al.  Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. , 2001, The New England journal of medicine.

[31]  L. Mofenson,et al.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.

[32]  W. Burman,et al.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. , 2001, American journal of respiratory and critical care medicine.

[33]  M. Altfeld,et al.  Consensus statement on antiretroviral treatment for AIDS in poor countries. , 2001 .

[34]  A. Harries,et al.  Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1 , 2001, The Lancet.

[35]  A. Berrebi,et al.  Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. , 2001, JAMA.

[36]  F. Plummer,et al.  Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi , 2001, The Pediatric infectious disease journal.

[37]  S. Hammer,et al.  Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.

[38]  F. Saulsbury.  Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Oxford,et al.  Antiretroviral therapy for HIV-2 infected patients. , 2001, The Journal of infection.

[40]  M. Cowles,et al.  Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. , 2000, The Journal of infectious diseases.

[41]  G. Ippolito,et al.  Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection , 2000, AIDS.

[42]  P. Pezzotti,et al.  Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. , 2000, JAMA.

[43]  M. Deltenre,et al.  Fatal liver failure associated with Nevirapine in a pregnant HIV patient: The first reported case , 2000 .

[44]  E. van der Ryst,et al.  Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[45]  M. Narita,et al.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. , 1998, American journal of respiratory and critical care medicine.

[46]  R. Brettle.  Correlation between total and CD4 lymphocyte counts in HIV infection , 1997, International Journal of STD and AIDS.

[47]  E. Beck,et al.  Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect , 1996, International journal of STD & AIDS.

[48]  A E Ades,et al.  Age-related reference ranges: significance tests for models and confidence intervals for centiles. , 1994, Statistics in medicine.

[49]  J. Sosenko,et al.  The relationship of total lymphocyte count to CD4 lymphocyte counts in patients infected with human immunodeficiency virus. , 1992, The American journal of the medical sciences.

[50]  D. Snider,et al.  Tuberculosis in patients with human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[51]  B. Kearney,et al.  Tenofovir Disoproxil Fumarate , 2004, Clinical pharmacokinetics.

[52]  L. Scott,et al.  Emtricitabine , 2012, Drugs.

[53]  C. Kityo,et al.  ,for the DART Trial Team. A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa: the DART trial , 2003 .

[54]  J. Pachón,et al.  Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis , 2002, Clinical pharmacokinetics.

[55]  W. Bishai,et al.  Issues in the treatment of Mycobacterium tuberculosis in patients with human immunodeficiency virus infection , 2001, AIDS.